Nexalin Technology

Nexalin Technology Treasury Stock

The Treasury Stock of Nexalin Technology (NXL) as of Nov 11, 2026 is 96.60 M USD. In the previous year, Treasury Stock was 88.31 M USD — a change of 9.38% (higher).

Treasury Stock

96.60 MUSD

YoY

9.38%

Last updated:

Treasury Stock of Nexalin Technology is 2025 96.60 M USD. Treasury Stock of Nexalin Technology was 2024 88.31 M USD. It decreases by 9.38% higher compared to the previous year.

The Nexalin Technology Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2019
60.03 M USD
Jan 1, 2020
63.02 M USD
Jan 1, 2021
69.00 M USD
Jan 1, 2022
77.82 M USD
Jan 1, 2023
80.24 M USD
Jan 1, 2024
88.31 M USD
Jan 1, 2025
96.60 M USD
The Nexalin Technology Treasury Stock history
YEARTreasury StockYoY
96.60 MUSD+9.38%
88.31 MUSD+10.06%
80.24 MUSD+3.10%
77.82 MUSD+12.78%
69.00 MUSD+9.50%
63.02 MUSD+4.98%
60.03 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology, Inc. generates revenue through the sale of its neurostimulation products, specifically the Generation 1 or Gen-1 device, which treats anxiety and insomnia using bioelectronic medical technology without drugs or psychotherapy. The company's products are non-invasive and undetectable, targeting individuals with mental health issues seeking relief without adverse side effects. Nexalin designs clinical trials for Gen-2, aimed at treating substance use disorders, particularly opiate-related issues, chronic pain, Alzheimer’s disease, and dementia, though Gen-2 is not yet commercially available. The firm focuses on medical applications where traditional treatments may be less effective or carry risks. The primary buyers of Gen-1 are patients with anxiety and insomnia who prefer non-pharmacological solutions. The company’s marketing emphasizes the device’s ease of administration and lack of side effects, appealing to those dissatisfied with conventional treatments. Nexalin’s clinical trials for Gen-2 target healthcare providers and institutions treating substance use disorders, Alzheimer’s, and dementia, positioning the product for future market entry in these high-demand segments. The firm’s revenue model relies on direct sales of Gen-1 and anticipated future sales of Gen-2 once clinical trials are completed and regulatory approvals are secured. Nexalin’s products operate through a unique waveform technology that combines varying voltages, currents, electromagnetic fields, and frequencies applied via electrodes on the head. This technology differentiates the company in the medical device market by offering a non-invasive alternative to drug-based therapies. The company’s focus on mental health and neurological conditions aligns with growing demand for innovative, side-effect-free treatments, enabling it to target specific patient segments seeking alternatives to traditional pharmaceuticals. Nexalin Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexalin Technology stock

Treasury Stock of Nexalin Technology is 96.60 M USD in 2025.

Treasury Stock of Nexalin Technology changed from 88.31 M USD to 96.60 M USD, representing a 9.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's Nexalin Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Nexalin Technology

All Key Metrics — Nexalin Technology